JP2017537948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537948A5 JP2017537948A5 JP2017531807A JP2017531807A JP2017537948A5 JP 2017537948 A5 JP2017537948 A5 JP 2017537948A5 JP 2017531807 A JP2017531807 A JP 2017531807A JP 2017531807 A JP2017531807 A JP 2017531807A JP 2017537948 A5 JP2017537948 A5 JP 2017537948A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- thiadiazol
- methoxy
- nicotinamide
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amide thiadiazole derivative Chemical class 0.000 claims 93
- 125000005976 1-phenylethyloxy group Chemical group 0.000 claims 25
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960003966 nicotinamide Drugs 0.000 claims 4
- 235000005152 nicotinamide Nutrition 0.000 claims 4
- 239000011570 nicotinamide Substances 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- MEGHFLIEWLLUNX-UHFFFAOYSA-N n-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(S1)=NN=C1C1=CC=NC=C1 MEGHFLIEWLLUNX-UHFFFAOYSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- QAUFWTBGWKZXOP-UHFFFAOYSA-N 3-methoxy-N-[5-(2-methylpyridin-4-yl)-1,3,4-thiadiazol-2-yl]-4-(1-phenylethoxy)benzamide Chemical compound COC=1C=C(C(=O)NC=2SC(=NN=2)C2=CC(=NC=C2)C)C=CC=1OC(C)C1=CC=CC=C1 QAUFWTBGWKZXOP-UHFFFAOYSA-N 0.000 claims 1
- HPJZCPNMGPFTJI-UHFFFAOYSA-N 3-methoxy-N-[5-(3-methylpyridin-4-yl)-1,3,4-thiadiazol-2-yl]-4-(1-phenylethoxy)benzamide Chemical compound COC=1C=C(C(=O)NC=2SC(=NN=2)C2=C(C=NC=C2)C)C=CC=1OC(C)C1=CC=CC=C1 HPJZCPNMGPFTJI-UHFFFAOYSA-N 0.000 claims 1
- JMVXUMLRFUGSTE-UHFFFAOYSA-N 4-[2-(dimethylamino)-1-phenylethoxy]-3-methoxy-N-[5-(2-methylpyridin-4-yl)-1,3,4-thiadiazol-2-yl]benzamide Chemical compound CN(CC(OC1=C(C=C(C(=O)NC=2SC(=NN=2)C2=CC(=NC=C2)C)C=C1)OC)C1=CC=CC=C1)C JMVXUMLRFUGSTE-UHFFFAOYSA-N 0.000 claims 1
- VQKAUTPDKIIAHI-UHFFFAOYSA-N 4-[2-(dimethylamino)-1-phenylethoxy]-3-methoxy-N-[5-(3-methylpyridin-4-yl)-1,3,4-thiadiazol-2-yl]benzamide Chemical compound CN(CC(OC1=C(C=C(C(=O)NC=2SC(=NN=2)C2=C(C=NC=C2)C)C=C1)OC)C1=CC=CC=C1)C VQKAUTPDKIIAHI-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100021217 Dual oxidase 2 Human genes 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 claims 1
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 claims 1
- NJSDMPYTJAYADS-UHFFFAOYSA-N N-[5-(3-fluoropyridin-4-yl)-1,3,4-thiadiazol-2-yl]-3-methoxy-4-phenylmethoxybenzamide Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=O)NC=2SC(=NN=2)C2=C(C=NC=C2)F)C=C1)OC NJSDMPYTJAYADS-UHFFFAOYSA-N 0.000 claims 1
- GRRIRLGOAKRDJW-UHFFFAOYSA-N N-[5-(3-fluoropyridin-4-yl)-1,3,4-thiadiazol-2-yl]-4-(2-hydroxy-1-phenylethoxy)-3-methoxybenzamide Chemical compound FC=1C=NC=CC=1C1=NN=C(S1)NC(C1=CC(=C(C=C1)OC(CO)C1=CC=CC=C1)OC)=O GRRIRLGOAKRDJW-UHFFFAOYSA-N 0.000 claims 1
- APMZBNNKDQHAPC-UHFFFAOYSA-N N-[5-(3-fluoropyridin-4-yl)-1,3,4-thiadiazol-2-yl]-4-(3-hydroxy-1-phenylpropoxy)-3-methoxybenzamide Chemical compound FC=1C=NC=CC=1C1=NN=C(S1)NC(C1=CC(=C(C=C1)OC(CCO)C1=CC=CC=C1)OC)=O APMZBNNKDQHAPC-UHFFFAOYSA-N 0.000 claims 1
- 108010002998 NADPH Oxidases Proteins 0.000 claims 1
- 102000004722 NADPH Oxidases Human genes 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000009378 breast hemangioma Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000005067 joint tissue Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
- OWDOHPZQTBVKOQ-UHFFFAOYSA-N n-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(S1)=NN=C1C1=CC=NC=C1 OWDOHPZQTBVKOQ-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14198597.8 | 2014-12-17 | ||
| EP14198597.8A EP3034500A1 (en) | 2014-12-17 | 2014-12-17 | Amido thiazole derivatives as NADPH oxidase inhibitors |
| PCT/IB2015/059659 WO2016098005A1 (en) | 2014-12-17 | 2015-12-16 | Amido thiadiazole derivatives as nadph oxidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537948A JP2017537948A (ja) | 2017-12-21 |
| JP2017537948A5 true JP2017537948A5 (OSRAM) | 2019-01-17 |
Family
ID=52146189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531807A Pending JP2017537948A (ja) | 2014-12-17 | 2015-12-16 | Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10130619B2 (OSRAM) |
| EP (2) | EP3034500A1 (OSRAM) |
| JP (1) | JP2017537948A (OSRAM) |
| KR (1) | KR20170094263A (OSRAM) |
| CN (1) | CN107207489A (OSRAM) |
| AU (1) | AU2015365465B2 (OSRAM) |
| BR (1) | BR112017012846A2 (OSRAM) |
| CA (1) | CA2971357A1 (OSRAM) |
| HK (1) | HK1245777A1 (OSRAM) |
| IL (1) | IL252928A0 (OSRAM) |
| MX (1) | MX2017007884A (OSRAM) |
| RU (1) | RU2017121044A (OSRAM) |
| WO (1) | WO2016098005A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| EP3479843A1 (en) * | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| CN112312913B (zh) | 2018-03-23 | 2024-03-08 | 詹森药业有限公司 | 化合物和其用途 |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| JP2022526890A (ja) * | 2019-03-22 | 2022-05-27 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| ES2968796T3 (es) * | 2019-05-31 | 2024-05-14 | Ideaya Biosciences Inc | Derivados de tiadiazolilo como inhibidores de la ADN polimerasa theta |
| EA202193251A1 (ru) | 2019-06-05 | 2022-03-10 | Эмори Юниверсити | Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций |
| CN110590706B (zh) * | 2019-11-06 | 2021-07-27 | 四平市精细化学品有限公司 | 一种n-甲基吡咯烷的制备方法 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN117083271A (zh) * | 2020-12-02 | 2023-11-17 | 伊迪亚生物科学有限公司 | 作为DNA聚合酶θ抑制剂的取代的噻二唑基衍生物 |
| TW202237595A (zh) * | 2020-12-02 | 2022-10-01 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物 |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
| KR102422881B1 (ko) * | 2021-11-08 | 2022-07-20 | (주)셀로스바이오텍 | 신규 옥사다이아졸 유도체 및 이의 용도 |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| TW202448435A (zh) * | 2023-02-28 | 2024-12-16 | 美商賽堤爾醫療公司 | 經取代之噻二唑基化合物 |
| TWI901073B (zh) * | 2023-04-13 | 2025-10-11 | 大陸商北京丹擎醫藥科技有限公司 | 噻二唑酮衍生物及其組合物和應用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| KR20040097375A (ko) * | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
| ATE466855T1 (de) * | 2002-10-30 | 2010-05-15 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
| JP2006520326A (ja) | 2003-02-28 | 2006-09-07 | ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン | 治療薬 |
| EP1616576A4 (en) | 2003-04-08 | 2010-02-10 | Mitsubishi Tanabe Pharma Corp | SPECIFIC NAD (P) H OXIDASE HEMMER |
| FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| US20110269141A1 (en) * | 2007-02-21 | 2011-11-03 | Reverse Proteomics Research Institute Co., Ltd. | Target protein and target gene for drug discovery, and screening method |
| TW201031645A (en) * | 2009-01-28 | 2010-09-01 | Sanofi Aventis | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof |
| KR20120026611A (ko) * | 2009-06-09 | 2012-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 헷지호그 신호전달의 피리딜-트리아진 억제제 |
| WO2011027359A2 (en) | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
| US8877742B2 (en) * | 2011-06-10 | 2014-11-04 | Glaxosmithkline Intellectual Property Limited | Compounds |
| GB201116017D0 (en) * | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
| EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
| EP2752196A1 (en) | 2013-01-03 | 2014-07-09 | Université Bordeaux Segalen | Selective nox-1 inhibitor peptides and uses thereof |
| US9688960B2 (en) | 2013-03-14 | 2017-06-27 | Eastern Virginia Medical School | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
-
2014
- 2014-12-17 EP EP14198597.8A patent/EP3034500A1/en not_active Withdrawn
-
2015
- 2015-12-16 RU RU2017121044A patent/RU2017121044A/ru unknown
- 2015-12-16 WO PCT/IB2015/059659 patent/WO2016098005A1/en not_active Ceased
- 2015-12-16 AU AU2015365465A patent/AU2015365465B2/en not_active Ceased
- 2015-12-16 MX MX2017007884A patent/MX2017007884A/es unknown
- 2015-12-16 US US15/536,800 patent/US10130619B2/en active Active
- 2015-12-16 JP JP2017531807A patent/JP2017537948A/ja active Pending
- 2015-12-16 KR KR1020177017800A patent/KR20170094263A/ko not_active Withdrawn
- 2015-12-16 EP EP15820629.2A patent/EP3233847A1/en not_active Withdrawn
- 2015-12-16 BR BR112017012846A patent/BR112017012846A2/pt not_active Application Discontinuation
- 2015-12-16 CN CN201580074696.5A patent/CN107207489A/zh active Pending
- 2015-12-16 HK HK18105173.8A patent/HK1245777A1/zh unknown
- 2015-12-16 CA CA2971357A patent/CA2971357A1/en not_active Abandoned
-
2017
- 2017-06-15 IL IL252928A patent/IL252928A0/en unknown
-
2018
- 2018-10-16 US US16/161,198 patent/US20190046515A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537948A5 (OSRAM) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| US20190345138A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2019529484A5 (OSRAM) | ||
| RU2312105C2 (ru) | N-пиразинилфенилсульфонамиды и их применение при лечении опосредованных хемокинами заболеваний | |
| JP2016522246A5 (OSRAM) | ||
| JP2017533968A5 (OSRAM) | ||
| JP2019505595A5 (OSRAM) | ||
| JP2009513703A5 (OSRAM) | ||
| JP2017508766A5 (OSRAM) | ||
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2014521653A5 (OSRAM) | ||
| JP2010533158A5 (OSRAM) | ||
| JP2010508338A5 (OSRAM) | ||
| JP2013531055A5 (OSRAM) | ||
| JP2017512786A5 (OSRAM) | ||
| JP2021502387A5 (OSRAM) | ||
| JP2020520357A5 (OSRAM) | ||
| JP2020516671A5 (OSRAM) | ||
| JP2014523400A5 (OSRAM) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| JP2016523976A5 (OSRAM) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета |